Boston Scientific Investment Agreement with Exclusive Option to Acquire Farapulse, Inc.
September 21, 2020
Boston Scientific Corporation signed an investment agreement that includes an exclusive option to acquire Farapulse, Inc., a privately held developer of pulsed field ablation technology for atrial fibrillation and other cardiac arrhythmias. Farapulse’s system uses irreversible electroporation (pulsed electric fields) to ablate heart tissue without thermal energy. The platform is investigational and not available for sale.
- Targets
- Farapulse, Inc.
- Industry
- Medical Devices
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Boston Scientific Makes $1.5 Billion Investment in MiRus LLC for Option to Acquire TAVR Business
May 18, 2026
Medical Devices
Boston Scientific Corporation invested $1.5 billion for an approximately 34% equity stake in privately held MiRus LLC. Under the investment agreement, Boston Scientific received an exclusive option to acquire MiRus’s SIEGEL balloon-expandable TAVR system business for up to $3 billion in additional cash payments, subject to clinical and regulatory milestones and closing conditions.
-
I-Pulse Acquires CSI Technologies to Expand U.S. High-Energy Capacitor Manufacturing
March 20, 2026
Industrial Services
I-Pulse, a pulsed power technology company, announced it acquired CSI Technologies, a Vista, California-based manufacturer of high-energy, high-voltage capacitors for industrial, medical, and defense applications. The acquisition is intended to expand I-Pulse’s U.S. manufacturing capabilities, strengthen the supply chain, and speed development and deployment of pulsed power technologies through integrated capacitor design and production expertise.
-
Boston Scientific to Acquire Nalu Medical, Inc.
October 17, 2025
Healthcare Services
Boston Scientific entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on minimally invasive chronic pain neuromodulation. The deal includes an upfront cash payment of approximately $533 million for the remaining equity not already owned by Boston Scientific, with Boston Scientific expecting closing in the first half of 2026.
-
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
November 4, 2024
Medical Devices
Boston Scientific Corporation entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company, to complement its electrophysiology portfolio with Cortex’s diagnostic mapping technology for complex atrial fibrillation. Cortex’s OptiMap System uses a basket catheter and proprietary algorithm to identify atrial fibrillation triggers outside the pulmonary veins, which is intended to support more targeted ablation strategies.
-
Electromedical Products International Acquires Pulvinar Neuro
March 17, 2022
Medical Devices
Electromedical Products International (EPI) has acquired Pulvinar Neuro, a research-oriented medical device company focused on closed-loop neuromodulation and digital therapeutics. The deal expands EPI's scientific and research capabilities to accelerate development and commercialization of Pulvinar's transcranial alternating current stimulation (tACS), individualized feedback stimulation, and cloud-enabled digital therapeutics.
-
Boston Scientific Acquires Baylis Medical Company Inc.
October 6, 2021
Medical Devices
Boston Scientific Corporation entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition is expected to expand Boston Scientific’s electrophysiology and structural heart portfolios by adding the RF NRG and VersaCross transseptal platforms and related guidewires, sheaths, and dilators.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.